Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745.

    Article  CAS  PubMed  Google Scholar 

  2. Marin D, Bazeos A, Mahon F-X, Eliason L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol; e-pub ahead of print 12 April 2010.

  3. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264.

    Article  CAS  PubMed  Google Scholar 

  4. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133–1134.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27: 3642–3649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371–2378.

    CAS  PubMed  Google Scholar 

  7. Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517–2525.

    Article  CAS  PubMed  Google Scholar 

  8. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J S Khorashad.

Ethics declarations

Competing interests

D Marin, JF Apperley, JM Goldman, D Milojkovic and K Rezvani receive honoraria and/or research funds from Novartis Pharmaceuticals. However, Novartis had no role in the design of the study, collection of the data or the decision to publish.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bazeos, A., Marin, D., Reid, A. et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24, 1243–1245 (2010). https://doi.org/10.1038/leu.2010.86

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.86

This article is cited by

Search

Quick links